Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rezpegaldesleukin - Nektar Therapeutics

Next Previous
Drug Profile

Rezpegaldesleukin - Nektar Therapeutics

Alternative Names: IL-2 conjugate; Interleukin-2 conjugate; LY-3471851; NKTR-358; PEG-conjugated rhIL-2; REZPEG - Nektar Therapeutics

Latest Information Update: 20 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nektar Therapeutics
  • Developer Eli Lilly and Company; Nektar Therapeutics
  • Class Anti-inflammatories; Antihyperglycaemics; Antipsoriatics; Interleukins; Polyethylene glycols; Recombinant proteins; Skin disorder therapies
  • Mechanism of Action Interleukin 2 modulators; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Alopecia areata; Systemic lupus erythematosus; Type 1 diabetes mellitus
  • Discontinued Psoriasis; Ulcerative colitis

Most Recent Events

  • 13 Aug 2026 Nektar Therapeutics plans a phase III registrational trial for Alopecia areata in early 2027
  • 14 Jul 2026 Nektar Therapeutics initiates phase-III ZENITH AD-2 clinical trials in Atopic dermatitis (In adolescents, In the elderly, In adults) in USA (SC) (NCT07711418)
  • 02 Jul 2026 Phase-III clinical trials in Atopic dermatitis (In adolescents, In the elderly, In adults) in USA (SC) (NCT07690371)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top